×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XNCR – xencor, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XNCR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
11:56 am
xncr
Incyte announces EU approval of Xencor-partnered lymphoma therapy [Seeking Alpha]
Medium
Report
Incyte announces EU approval of Xencor-partnered lymphoma therapy [Seeking Alpha]
12/17
07:06 am
xncr
Xencor (NASDAQ:XNCR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Xencor (NASDAQ:XNCR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/16
04:43 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/10
04:12 am
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/9
07:00 am
xncr
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Medium
Report
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
12/2
03:47 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/24
09:04 am
xncr
Xencor (NASDAQ:XNCR) was given a new $29.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Xencor (NASDAQ:XNCR) was given a new $29.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
xncr
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
11:13 am
xncr
Form SCHEDULE 13G/A Xencor Inc Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A Xencor Inc Filed by: VANGUARD GROUP INC
11/14
12:20 pm
xncr
Form SCHEDULE 13G/A Xencor Inc Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A Xencor Inc Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
08:35 am
xncr
Form SCHEDULE 13G Xencor Inc Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SCHEDULE 13G Xencor Inc Filed by: RTW INVESTMENTS, LP
11/5
04:04 pm
xncr
Form 10-Q Xencor Inc For: Sep 30
Low
Report
Form 10-Q Xencor Inc For: Sep 30
11/5
04:02 pm
xncr
Form 8-K Xencor Inc For: Nov 05
Low
Report
Form 8-K Xencor Inc For: Nov 05
10/31
11:42 am
xncr
Form SCHEDULE 13G/A Xencor Inc Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Xencor Inc Filed by: VANGUARD GROUP INC
10/24
01:57 pm
xncr
Form 8-K Xencor Inc For: Oct 24
Low
Report
Form 8-K Xencor Inc For: Oct 24
10/17
04:56 pm
xncr
Form SCHEDULE 13G Xencor Inc Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SCHEDULE 13G Xencor Inc Filed by: BIOTECHNOLOGY VALUE FUND L P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
13.8%
5/9 Xencor Reports First Quarter 2019 Financial Results 10.3%
6/30 Xencor: Multiple Data Readouts In Second Half Of 2019 For This 'Picks And Shovels' Play [Seeking Alpha] 7.2%
2/5 Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments 6.1%
3/4 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $28.00 price target on the stock. 5.7%
3/25 Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 5.3%
8/8 Xencor Inc (NASDAQ: XNCR) had its price target raised by analysts at Canaccord Genuity from $45.00 to $52.00. They now have a "buy" rating on the stock. 5.0%
3/23 Form 4 Xencor Inc For: Mar 19 Filed by: STAFFORD JOHN S III 4.7%
6/27 Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. 3.6%
1/30 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. 3.2%
5/9 Xencor Reports First Quarter 2019 Financial Results 10.3%
6/30 Xencor: Multiple Data Readouts In Second Half Of 2019 For This 'Picks And Shovels' Play [Seeking Alpha] 7.2%
2/5 Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments 6.1%
3/4 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $28.00 price target on the stock. 5.7%
3/25 Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 5.3%
8/8 Xencor Inc (NASDAQ: XNCR) had its price target raised by analysts at Canaccord Genuity from $45.00 to $52.00. They now have a "buy" rating on the stock. 5.0%
3/23 Form 4 Xencor Inc For: Mar 19 Filed by: STAFFORD JOHN S III 4.7%
6/27 Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. 3.6%
1/30 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. 3.2%
TOP News Decliners
8/6
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
-20.0%
12/26 Form 4 Xencor Inc For: Dec 20 Filed by: STAFFORD JOHN S III -8.4%
5/12 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock. -7.5%
4/29 Form DEF 14A Xencor Inc For: Jun 25 -6.7%
8/21 Form 4 Xencor Inc For: Aug 19 Filed by: Desjarlais John R -6.1%
8/22 Form 4 Xencor Inc For: Aug 21 Filed by: Kuch John J -5.6%
1/8 Form 4 Xencor Inc For: Jan 06 Filed by: STAFFORD JOHN S III -5.0%
4/30 Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 -4.0%
1/25 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $42.00 price target on the stock. -3.9%
2/26 Xencor Inc (NASDAQ: XNCR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.7%
12/26 Form 4 Xencor Inc For: Dec 20 Filed by: STAFFORD JOHN S III -8.4%
5/12 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock. -7.5%
4/29 Form DEF 14A Xencor Inc For: Jun 25 -6.7%
8/21 Form 4 Xencor Inc For: Aug 19 Filed by: Desjarlais John R -6.1%
8/22 Form 4 Xencor Inc For: Aug 21 Filed by: Kuch John J -5.6%
1/8 Form 4 Xencor Inc For: Jan 06 Filed by: STAFFORD JOHN S III -5.0%
4/30 Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 -4.0%
1/25 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $42.00 price target on the stock. -3.9%
2/26 Xencor Inc (NASDAQ: XNCR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: